Integration of Genomics Into Treatment: Are We There Yet? Am Soc Clin Oncol Educ Book 2017;37:569-574
Date
06/01/2017Pubmed ID
28561666DOI
10.1200/EDBK_175166Scopus ID
2-s2.0-85052221916 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Using advances in genetic analysis to segment and direct treatment of multiple myeloma (MM) represents a way of maintaining therapeutic progress. Recent genetic analyses have opened the possibility of enhancing risk stratification approaches and of using different risk and biologic strata as part of clinical trials. The Myeloma Genome Project is a collaborative project that has compiled the largest set of cases with sequencing and have outcome data that are available for stratification purposes. Mutation-targeted treatment of the Ras pathway has been shown to be active in MM, but is compromised by the presence of the subclonal genetic variation typical of myeloma. Going forward, risk and biologically stratified therapy for MM looks to be a promising way of maintaining therapeutic progress, as does precision immunotherapy directed by the cellular context of the bone marrow.
Author List
Morgan GJ, Jones JRAuthor
Test W. User test user title in the Anesthesiology department at University of Wisconsin - MilwaukeeMESH terms used to index this publication - Major topics in bold
Bone MarrowGenome, Human
Genomics
Humans
Immunotherapy
Multiple Myeloma
Mutation
